1. Partin AW, Carter HB, Chan DW, et al. Prostate
spesific antigen in the staging of localized
prostate cancer: influence of tumor differentiation,
tumor volume and benign hyperplasia. J
Urol 1990;143: 747-753.
2. Epstein JI, Eggleston JC. Immunohistochemical
localisation of prostate spesific acid phospatase
and prostate spesific antigen in stage A2 adenocarcinoma
of prostate: Prognostic implications.
Hum Path 1984; 15: 853.
3. Pretlow TG, Yang B, et al. Tissue concentrations
of prostate spesific antigen in prostate carcinoma
and benign proostatic hyperplasia. Int J
Cancer 1991; 49: 645.
4. Naritoku WY, Taylor CR. A comparative study
of the use of the monoclonal antibodies using
three different immunohistochemical methods:
An evaluation of monoclonal and polyclonal antibodies
against human prostatic acid phosphatase.
J Histochem Cytochem 1982; 30: 253-
260.
5. Oesterling JE. Prostate spesific antigen:a critical
assesment of the most useful tumor marker
for adenocarcinoma of the prostate. J Urol 1991;
145: 907-912.
6. McCormack RT, Rittenhouse HG, Finlay JA, et
al. Molecular forms of prostate spesific antigen
and human kallikrein gene family: A new era.
Urology 1995; 45: 729-732.
7. Elganal AA, Ectors NL, Sunardhi-Widyaputra
S, et al. Detection of prostate spesific antigen in
pancreas and salivary glands: A potential impact
on prostate cancer over estimation. J Urol
1991; 156: 464-468.
8. Ford TF, Butcher DN, Masters JRW, et al. Immunocytochemical
localisation of prostate spesific
antigen: Spesifity and application to clinical
practise. Brit J Urol 1985; 57: 50-53.
9. Kırkalı Z, Mungan U, Yörükoğlu K. Prostat
Kanseri Patolojisi: Prostat Kanseri Güncel Yaklaş
õmlar Seminer Notları, Ed. Erözenci NA. İstanbul,
1997.
10.Sakai H, Yogi Y, Minami Y, et al. Prostate spesific
antigen and prostatic acid phosphatase immunoreactivity
as prognostic indicators of advanced
prostatic carcinoma. J Urol 1993; 149:
1020-1023.
11. Ito H, Yamaguchi K, Sumiya H, et al. Histochemical
study of R 1881-binding protein, prostate
acid phosphatase, prostate spesific antigen
and r-seminoproteinin prostatic cancer. Eur
Urol 1986; 12: 49-52.
12.Greskovich FJ, Johnson DE, Tenney DM, et al.
Prostate spesific antigen in patients with clinical
stage C prostate cancer: relation to lymph
node status and grade. J Urol 1991; 145: 798-
802.
13. Aihara M, Lebovitz RM, Wheeler TM, et al.
Prostate spesific antigen and Gleason grade: An
immunohistochemical study of prostate cancer.
J Urol 1994; 151: 1558-1564.
14.Stamey TA, Kabalin JN, Mc Neal JE, et al.
Prostate spesific antigen in the diagnosis and
treatment of adenocarcinoma of the prostate. J
Urol 1989; 141: 1076-1083.
